FDA Accepts Supplemental Application for Argatroban by Fresenius Kabi
The FDA has accepted a supplemental application for Argatroban submitted by Fresenius Kabi.
Asset / Drug
Drug and asset intelligence for Argatroban with 17 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental NDA for Argatroban in Sodium Chloride submitted by Accord Healthcare.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.